Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 90.7%

Neg 90.7% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.